{"commentary":{"count":71,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":27,"youtube":25,"podcast":15,"x_video":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05735184\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05735184","nct_id":"NCT05735184","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05735184. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy","label":"Dose Escalation: Ziftomenib with Venetoclax and Azacitidine in R/R NPM1-m (A-1)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy","label":"Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in R/R NPM1-m (A-1)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \\<0.05","label":"Dose Escalation: Ziftomenib with 7+3 in 1L NPM1-m/FLT3 wildtype (A-2)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \\<0.05","label":"Dose Validation/Expansion: Ziftomenib with 7+3 in 1L NPM1-m/FLT3 wildtype (A-2)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy","label":"Dose Validation/Expansion: Ziftomenib with Venetoclax in R/R NPM1-m (A-3)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax and Azacitidine in newly diagnosed NPM1-m AML patients","label":"Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in 1L NPM1-m (A-4)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy","label":"Dose Escalation: Ziftomenib with Venetoclax and Azacitidine in R/R KMT2A-r (B-1)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy","label":"Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in R/R KMT2A-r (B-1)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy","label":"Dose Escalation: Ziftomenib with 7+3 in 1L KMT2A-r (B-2)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive therapy","label":"Dose Validation/Expansion: Ziftomenib with 7+3 in 1L KMT2A-r (B-2)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with Venetoclax and Azacitidine in newly diagnosed KMT2A-r AML patients","label":"Dose Validation/Expansion: Ziftomenib with Venetoclax + Azacitidine in 1L KMT2A-r (B-3)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy","label":"Dose Escalation: Ziftomenib with 7+3+quizartinib in 1L NPM1-m/FLT3-ITD+ AML patients (C-1)","type":"EXPERIMENTAL"},{"description":"Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy","label":"Dose Validation/Expansion: Ziftomenib with 7+3+quizartinib in 1L NPM1-m/FLT3-ITD+ AML patients (C-1)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Mixed Lineage Leukemia Gene Mutation","Refractory AML","AML With Mutated NPM1","Acute Myeloid Leukemia Recurrent","Acute Myeloid Leukemia, in Relapse","NPM1 Mutation","KMT2Ar","Myeloid Sarcoma","Nucleophosmin 1-mutated Acute Myeloid Leukemia"],"enrollment":{"count":420,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ziftomenib","type":"DRUG"},{"name":"Venetoclax","type":"DRUG"},{"name":"Azacitidine","type":"DRUG"},{"name":"Daunorubicin","type":"DRUG"},{"name":"Cytarabine","type":"DRUG"},{"name":"Quizartinib","type":"DRUG"}],"last_update":"2026-03-13","lead_sponsor":"Kura Oncology, Inc.","official_title":"Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2030-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)","timeFrame":"During the first 28 days of ziftomenib in combination with SOC backbone treatment (1 cycle)"},{"measure":"Descriptive statistics of adverse events","timeFrame":"From Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment"},{"measure":"Complete remission (CR) rate","timeFrame":"Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first"}],"references":[{"citation":"Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Jun 2:blood.2026034043. doi: 10.1182/blood.2026034043. Online ahead of print.","pmid":"42227701","type":"DERIVED"}],"start_date":{"date":"2023-07-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","url":"https://clinicaltrials.gov/study/NCT05735184"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05735184"}